Ranbaxy to resume generic Lipitor production for U.S
(Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Friday it will resume production of its version of Pfizer's cholesterol fighter Lipitor for sale in the United States after resolving the issues that led to a November recall. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
RCCT of Atorvastatin in Reducing the Severity of SepsisRCCT of Atorvastatin in Reducing the Severity of Sepsis
Do statin naive patients with sepsis have lower severity of illness with a daily dose of atorvastatin? Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2013 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news
Initiating Atorvastatin in Severe Sepsis Isn't Helpful: StudyInitiating Atorvastatin in Severe Sepsis Isn't Helpful: Study
Starting atorvastatin in critically ill patients with severe sepsis did not reduce inflammation or improve survival in a phase II study from the ANZICS Clinical Trials Group. Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 8, 2013 Category: Intensive Care Tags: Critical Care News Source Type: news
Are Drugs for Ultra-Rare Diseases the Future of Biotech? Francois Nader of NPS Weighs In
Over the last ten years, the global pharmaceutical industry has undergone dramatic changes. In the 1990s, big drug companies made hundreds of billions of dollars selling slightly improved versions of their competitors’ drugs; think of the epic battle between cholesterol-lowering drugs Lipitor and Zocor. Since then, however, an entirely new business model has emerged: developing drugs for rare, or “orphan” diseases, which are far easier to get through the FDA, and for which companies can charge significantly higher prices. The latest entry into the field is NPS Pharmaceuticals’ Gattex, which was approved last Decemb...
Source: Forbes.com Healthcare News - February 5, 2013 Category: Pharmaceuticals Authors: Avik Roy Source Type: news
Medicines Co. Licenses Rights to Cholesterol Drug
The drug inhibits the protein PCSK9 and might one day be used to treat millions of people whose cholesterol is not lowered enough by common statins, such as Lipitor. (Source: NYT Health)
Source: NYT Health - February 4, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Biogen Idec Inc BIIB NASDAQ Cambridge (Mass) Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Roche Holding A G RHHBY Other OTC Sanofi SA SNY NYSE Cholesterol Amgen Inc AMGN NASDAQ Alnylam Pharmaceuticals Inc ALNY NASDAQ Regeneron Pharmaceuti Source Type: news
Outsource Or Manage Internally? Pharma Logistics, 9-10 April 2013, Vienna, Austria
"The current trend in pharma logistics is the shift from blockbuster drugs. 6 out of 10 top selling drugs will lose their patents in one year, so there will be increase in the use of generic drugs," Sebastiaan Scholte, Chairman at Cool Chain Association, pointed out when speaking about the latest developments. These trends influence drug manufacturers and make them rethink their strategies. Already without medications like Lipitor and Plavix bolstering their bottom lines, manufacturers have to cut costs in order to stay competitive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 31, 2013 Category: Consumer Health News Tags: Conferences Source Type: news
Pfizer hints core drugs unit may be split
The chief’s comments come as it reports a jump in fourth-quarter profits, as proceeds from the sale of its nutrition business offsets lost Lipitor sales (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 29, 2013 Category: Pharmaceuticals Source Type: news
Merck Resubmits Data to FDA for Ezetimibe/Atorvastatin ComboMerck Resubmits Data to FDA for Ezetimibe/Atorvastatin Combo
The resubmission of the updated new drug application includes the additional data requested by the FDA, and the company expects the FDA review to be completed in the first half of 2013. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
